COVID Vaccine Developer/Manufacturer Announcements

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases
Vaxzevria significantly boosted antibody levels against Omicron
23 December 2021
:: University of Oxford study supports use of Vaxzevria as third dose booster against Omicron
:: Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities
23 December 2021
:: University of Oxford study supports use of Vaxzevria as third dose booster against Omicron
:: Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Bharat Biotech
Press Releases
Jan 08: COVAXIN® (BBV152) booster dose study shows promising results
The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated
long-term safety with no serious adverse events.

BioCubaFarma – Cuba
Últimas Noticias
Casi el 70% de la población cubana ya ha sido inmunizada contra la COVID-19.
20 de Diciembre, 2021

 

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News
Jan 5,2022 Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA

Jan 5,2022 Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai

 

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases
Jan 06, 2022 United States
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

Dec 30, 2021 United States
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Separate analysis showed Johnson & Johnson COVID-19 vaccine booster generated 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against Omicron

 

Moderna
Press Releases
January 5, 2022
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

December 27, 2021
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022

December 27, 2021
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna’s COVID-19 Booster Vaccine in 2022

December 20, 2021
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

 

Novavax
Press Releases
Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
Dec 31, 2021

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
Dec 28, 2021

Novavax and SK bioscience Expand Manufacturing Agreement
Dec 23, 2021

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
Dec 22, 2021

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
Dec 21, 2021

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine
Dec 21, 2021

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine
Dec 20, 2021

 

Pfizer
Recent Press Releases
01.05.2022
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

01.04.2022
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19

01.04.2022
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

01.03.2022
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

12.22.2021
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

12.22.2021
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

 

Sanofi Pasteur
Press Releases
December 15 2021 Press releases
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation

 

Serum Institute of India
NEWS & ANNOUNCEMENTS
Tuesday, December 28, 2021
Serum Institute of India and Novavax Receive Emergency Use Authorization in India for COVOVAX™

 

Sinopharm/WIBPBIBP
News – No new digest announcements identified

 

Sinovac
Press Releases
SINOVAC CoronaVac® Shows Good Safety in Pregnant and Postpartum Women
2021/12/29

South Africa Phase III Clinical Study Shows SINOVAC CoronaVac® Safe for Children as Young as 6 Months
2021/12/2

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media – No new digest announcements identified

 

Merck
News releases
December 24, 2021
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan

December 23, 2021
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

December 22, 2021
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

 

Novartis
News – No new digest announcements identified

 

SK Biosciences
Press releases
SK bioscience-Novavax Extend Collaboration and Contract Manufacturing Agreements of COVID-19 Vaccine
SK-Novavax amended the Collaboration and License agreement for contract manufacturing of ‘NVX-CoV237…
2021. 12. 24

 

Valneva
Press Releases
January 5, 2022
Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001

December 23, 2021
Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate